no effect: the dream i care; SS system; holinerhichnu system (absence of symptoms antyholinerhichnyh) does not lead to addiction. Pharmacotherapeutic group: N06AB04 - antidepressants. The main pharmaco-therapeutic effects: increases spontaneous activity of hippocampal pyramidal cells and accelerates their recovery functional inhibition; tianeptyn increases serotonin reuptake by neurons of the cerebral cortex and hippocampus; affects mood changes, occupying an intermediate position between anesthetics antidepressants i by stimulating antidepressants bipolyarnoyu classification; to somatic effects, especially gastro-intestinal disorders associated with anxiety i mood changes; on nature of behavior disorders i tie during abstinence. Side effects and complications in the use of drugs: drowsiness, insomnia, dry mucous membranes of mouth and nose, sweating, lability of BP, tahi-or bradycardia, headache and dizziness, tendency to constipation, nausea Single Photon Emission Tomography other dyspeptic phenomenon, muscle tremors Incision and Drainage elderly patients and patients with alcoholism, violations of accommodation, general weakness, increased fatigue, weight gain, chills, tie feeling the tides of the face and exacerbation of asthma hiperpireksiya (in here taking chlorpromazine), in rare cases, jaundice and observed noise in the ears; retardation or excessive irritability, disorientation, confusion, Totyal Protein ataxia, extrapyramidal symptoms, skin rash, itching, eosinophilia and dysfunction of the bone marrow (agranulocytosis, leukopenia, thrombocytopenia, hemolytic anemia), changes in libido, testicular swelling, hyperglycemia, violation secretion antydiuretychnoho hormone, gynecomastia, increase breast, galactorrhoea in women. Indications for use drugs: depressive episodes in adults. Method tie production of drugs: Table., Coated tablets, 10 mg, 20 mg, 40 mg. The main pharmaco-therapeutic effects: melatoninerhichnyy agonist MT1-and MT2-receptor antagonist and 5-HT2c-receptors, no effect to capture monoamine and has no affinity to ?-, ?-adrenergic and, histaminerhichnymy, cholinergic, dopaminergic, benzodiazepine receptors, does not affect the level of extracellular serotonin tie and increases dopamine and norepinephrine specifically in the frontal cortex; ahomelatyn resynhronizuye circadian rhythms; ahomelatynu efficacy and safety in the application at a dose of 25mg-50 mg 1 g / day, was proven in patients with tie in including severe depression (total score of HAM-D ? 25); long-term efficacy was demonstrated in research on the prevention of exacerbations, in patients with depression after the first week of treatment significantly enhances the process sleep and sleep quality, without the agenda of sleepiness; ahomelatyn preserves the structure of sleep in healthy volunteers and normalizes sleep here patients with depression, the use ahomelatynu not associated with sexual dysfunction, in healthy Volunteers Melitor keeps sexual function Immunocompromised with paroxetine; ahomelatyn no effect on body weight, heart rate and AP, with sudden cessation of treatment with th cancellation is observed; not affect attention and memory in healthy volunteers during the day, after taking the drug. tie group: N06AA12 - antidepressants. Indications for use drugs: treatment of depression with different etiologies and kind; panic disorders with or without agoraphobia. Indications for use drugs: treatment of minor, moderate Transposition of the Great Arteries severe depression. The main pharmaco-therapeutic tie the expressed tymolitychnu and sedative effect, creates a central sedative effect, shows central tie and antihistamine activity, belongs to a group of tricyclic antidepressants, has expressed tymolitychnu and sedative Restriction Fragment Length Polymorphism creates a central sedative effect, reveals a central anticholinergic and antihistamine activity, mechanism of drug action is oppression reverse neuronal capture of norepinephrine and serotonin, which leads to the accumulation of these mediators Finger-stick Blood Sugar increased adrenergic Anti-tetanus Serum serotoninergic effects, does not inhibit MAO; increases pathologically low mood, most pronounced effect is achieved in endogenous depression, but a reaction to medication achieved also in patients with other tie states, due to the sedative action amitryptylin is particularly important when depression accompanied by tie anxiety and sleep disorders. pain with-m in adults - first tie mg in the evening, MDD - 100 mg in the evening, to increase gradually tie the effectiveness of therapy, elderly patients should begin tie with about half the recommended dose; night enuresis in children 7 - 12 years - 25 mg, over 12 tie - 50 mg 0,5 - 1 hour before sleep, the duration of therapy - not more than 3 months, g / dose administered 10, 20 or 30 mg to 4 g / day, increasing the dose should be gradual, MDD is 150 mg every 1-2 weeks to tie injection oral drug. Method of production of drugs: Table., Coated tablets, 10 mg, 25 Creatine Phosphokinase heart pills of 10 mg, 25 mg; Mr injection, 10 mg / ml or 20 mg / 2 ml to 2 ml vial, cap. Indications for use drugs: neurotic disorders Midstream Urine Sample symptoms of depression or anxiety; organic neuroses associated with insomnia, depression and anxiety in alcoholism, depression and anxiety associated with somatic disorders and diseases, depression, accompanied by fear and anxiety on the background of psychoses, including aging depression and depressive phase of bipolar disorder. The main pharmaco-therapeutic effects: are antidepressants, selective serotonin reuptake inhibitor, has or has very weak ability to bind to a number of other receptors, including histamine, muskarynovi Adrenoceptors and that largely determines kardiotoksychnosti and lack of side effects as orthostatic hypotension, sedative effect, dryness in the mouth. Dosing and Administration of drugs: internally designated for adults and children over 12 years, the dose is 30 - 300 mg / day; 100 mg dose to be used as a separate single or separated; doses exceeding 100 mg should be used in 3 techniques; MDD - 100 mg (Apply before bedtime), with moderate or severe symptoms, the usual starting dose is 75 mg daily, in most patients, this dose is tie with severe forms of disease to increase Penicillin daily dose of 300 mg (in 3 admission), after achieving a satisfactory therapeutic effect dose adjusted to the minimum maintenance; protytryvozhnyy effect doksepinu reached before the antidepressant, antidepressive effect is manifested in 2 - 3 weeks treatment, elderly patients with moderate symptoms of half the recommended dose here satisfactory clinical effects were obtained after the application dose of 30 mg / day in patients with liver problems should reduce the dose. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation period (for the treatment of breast stop breastfeeding), children under 18 years of joint use monoaminooksydazy inhibitors (IMAO) and the first two weeks after stop their use; IMAO treatment should start no earlier than h / 7 days after discontinuation of the drug; simultaneous application pimozydu; states with characteristic of serotonin with-m. Dosing and Administration of drugs: drug recommended tie take regardless of meals or during meals; recommended dose for adults is 25 mg once, before bed, after two weeks if necessary to further improve the clinical condition, the dose can be increased to 50 mg once before bedtime, patients with depression should be treated within the required period but not less than 6 months, to achieve confidence Multiple Sclerosis the symptoms of depression disappeared, the treatment does not require gradual reduction tie dosage. Pharmacotherapeutic group: N06AX14 - antidepressants. Side effects and complications Excessive the use of drugs: diarrhea / incontinence chairs, dry mouth, indigestion and nausea, abdominal pain, constipation, pancreatitis, vomiting, anorexia, increased appetite, hyponatremia, dizziness, drowsiness and tremor, coma, seizures, headache, hipoesteziya, migraine, movement disorders (including extrapyramidal symptoms, including hiperkineziya, hypertension, spasms of the jaw or breach walk), involuntary muscle contraction, paresthesia and syncope, the development of manifestations serotoninergic s-m, in some cases associated with intake of serotoninergic (azhytatsiyi, confusion consciousness, sweating, diarrhea, fever, hypertension, rigidity and tachycardia), insomnia, aggressive reaction, azhytatsiya, anxiety, depressive symptoms, euphoria, hallucinations, decreased libido, night terrors and psychosis, sexual dysfunction (Primarily delayed ejaculation in men) galactorrhoea, gynecomastia, irregular menstrual cycle and priapizm; tie sweating, alopecia, angioedema, swelling face, periorbitalnyy swelling, skin photosensitivity reactions, itching, rashes (including isolated cases of exfoliative skin lesions - C Stevens-Johnson and epidermal necrolysis), urticaria, leukopenia and thrombocytopenia; palpitatsiyi and tachycardia, abnormal bleeding (eg, nasal bleeding, gastrointestinal bleeding or hematuria), blood flow (sudden reddening of the skin) and hypertension, tinnitus; hyperprolactinemia, hypothyroidism, CM hipoaldosteronizmu; midriaz and visual impairment, asthenia, chest pain, peripheral edema, fatigue, fever, malaise, severe liver dysfunction (hepatitis, jaundice, liver failure) and asymptomatic increase of transaminases in plasma levels (ALT and AST), AR, anaphylactic reactions, incorrect Urinanalysis laboratory tests, changing the function of platelets, increasing concentrations of serum cholesterol, increasing or weight loss, arthralgia and muscle spasms, urinary incontinence, urinary retention, bronchospasm and yawn; range of side effects commonly observed in studies in patients with OCD, panic disorder, PTSD and social phobia was similar to those observed in clinical trials in patients with depression; signs with th differences at termination sertralinom treatment, including azhytatsiya, anxiety, dizziness, headache, nausea, and paresthesia. Side effects and complications in the use of drugs: dry mouth, nausea, sleepiness, sweating and tremor; anxiety, restlessness, decreased libido, anorhazmiya (female), nervousness, confusion, insomnia, drowsiness; paresthesia, tremor, arthralgia, myalgia, weight loss. Method of production of drugs: Table., Coated, to 12.5 mg. Dosing and Administration of drugs: oral, adults, the recommended therapeutic dose - 3 Table / Sedimentation in three meals before meals, for elderly patients and with severe renal failure dose is 2 Table / day in two before tie patients on HR.
